ArticleDiabetes, obesity & metabolism2026
Risk of acute pancreatitis with DPP-4 inhibitors versus SGLT2 inhibitors in medication-naïve individuals with diabetes: A target trial emulation.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsWe investigated whether dipeptidyl peptidase-4 inhibitor (DPP-4i) use was associated with a higher risk of acute pancreatitis compared with sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication-naïve individuals. MATERIALS AND
methodsIn this target trial emulation study of medication-naïve individuals with diabetes from a Japanese claims database from April 2014 to August 2023, the risk of acute pancreatitis was compared between new users of DPP-4is and new users of SGLT2is. After adjusting for confounders using propensity score-based overlap weighting, we used Cox proportional hazards models for hospitalization due to acute pancreatitis to estimate the hazard ratio (HR) and 95% confidence interval (CI) within the groups in both the intention-to-treat and per-protocol analyses. We also calculated incidence rate differences (IRDs) per 1000 person-years.
resultsThis study included 26 133 DPP4-i and 6497 SGLT2i users. DPP-4i use was not significantly associated with a higher risk of acute pancreatitis compared with SGLT2i use; the adjusted HRs were 0.97 (95% CI, 0.51-1.83) and 1.11 (95% CI, 0.54-2.27), with IRDs of -0.05 (95% CI, -0.97 to 0.87) and 0.15 (95% CI, -0.86 to 1.15) per 1000 person-years in the intention-to-treat and per-protocol analyses, respectively.
conclusionsAlthough small differences cannot be excluded given the width of the CIs for the estimated HRs, the small IRDs observed suggest that any potential difference, if present, is likely to be clinically modest. Therefore, acute pancreatitis risk may not be a major determinant when selecting initial therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.